Kai Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kai Wu has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Binghui Li
The Third Medical Center, PLA General Hospital, China
1 shared publication - Lin Zhang
The Third Medical Center, PLA General Hospital, China
1 shared publication - Yanhong Hou
The Third Medical Center, PLA General Hospital, China
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Preprints.org
From Morphology to Microbiology: Closing the Diagnostic–Therapeutic Loop for Helicobacter pylori at the Endoscope Tip
Despite four decades of therapeutic progress, Helicobacter pylori eradication continues to decline in high-resistance regions, where clarithromycin resistance exceeds the 15% threshold that renders empirical therapy unreliable. Maastricht VI and the 2024 American College of Gastroenterology guideline mandate susceptibility-directed therapy wherever predicted efficacy falls below 80%, yet no existing method delivers phenotypic susceptibility results within the endoscopy encounter: culture requires 5–7 days and succeeds in roughly half of biopsies, while molecular assays interrogate only known mutations and cannot assess bacterial viability. The result is a persistent “open loop” of biopsy, delayed reporting, empirical therapy, and recurrent failure. Fluorescence rapid on-site evaluation (F-ROSE) can close this loop. In published cohorts, dual-fluorescence viability staining visualized viable organisms—including viable but non-culturable coccoid forms—within 25–30 minutes, with a sensitivity of 0.947 in a 317-patient comparison. A peer-reviewed proof-of-concept study showed that the fluorescence residual rate after 1 hour of antibiotic exposure provides a culture-free phenotypic susceptibility readout directly from biopsies, with 100% sensitivity for amoxicillin and levofloxacin. Combined with same-visit tailored therapy and a structured training program that raised interpretation accuracy from 58.1% to 86.8%, these steps form an integrated paradigm we designate HP-REVISE (H. pylori real-time evaluation by visual imaging and phenotypic susceptibility estimation): SEE, TEST, TREAT, TEACH—all at the endoscope tip. Here we set out the rationale, the published evidence, the unresolved biological and standardization questions, and the registered multicentre trial that will determine whether the loop improves eradication at scale.
- 9 November 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Morphology to Microbiology: Closing the Diagnostic–Therapeutic Loop for Helicobacter pylori at the Endoscope Tip
Despite four decades of therapeutic progress, Helicobacter pylori eradication continues to decline in high-resistance regions, where clarithromycin resistance exceeds the 15% threshold that renders empirical therapy unreliable. Maastricht VI and the 2024 American College of Gastroenterology guideline mandate susceptibility-directed therapy wherever predicted efficacy falls below 80%, yet no existing method delivers phenotypic susceptibility results within the endoscopy encounter: culture requires 5–7 days and succeeds in roughly half of biopsies, while molecular assays interrogate only known mutations and cannot assess bacterial viability. The result is a persistent “open loop” of biopsy, delayed reporting, empirical therapy, and recurrent failure. Fluorescence rapid on-site evaluation (F-ROSE) can close this loop. In published cohorts, dual-fluorescence viability staining visualized viable organisms—including viable but non-culturable coccoid forms—within 25–30 minutes, with a sensitivity of 0.947 in a 317-patient comparison. A peer-reviewed proof-of-concept study showed that the fluorescence residual rate after 1 hour of antibiotic exposure provides a culture-free phenotypic susceptibility readout directly from biopsies, with 100% sensitivity for amoxicillin and levofloxacin. Combined with same-visit tailored therapy and a structured training program that raised interpretation accuracy from 58.1% to 86.8%, these steps form an integrated paradigm we designate HP-REVISE (H. pylori real-time evaluation by visual imaging and phenotypic susceptibility estimation): SEE, TEST, TREAT, TEACH—all at the endoscope tip. Here we set out the rationale, the published evidence, the unresolved biological and standardization questions, and the registered multicentre trial that will determine whether the loop improves eradication at scale.